STOCK TITAN

Ocugen to Present at May 2024 Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ocugen, Inc. announced that its senior executives will present at two investor conferences in May 2024, highlighting the Company's gene and cell therapy clinical development progress, including the OCU400 Phase 3 clinical trial for retinitis pigmentosa. Dr. Shankar Musunuri and Dr. Huma Qamar will participate in the events.

Positive
  • None.
Negative
  • None.

MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder, Ocugen, will present at The Citizens JMP Life Sciences Conference taking place at the New York Hilton Midtown from May 13 – 14, 2024. Additionally, Dr. Huma Qamar, Chief Medical Officer, Ocugen, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024.

Details of the presentations are as follows:

The Citizens JMP Life Sciences Conference

Location: New York Hilton Midtown

Date: Monday, May 13, 2024

Time: 9:30 – 9:55 a.m. ET

Live Webcast: Available on Citizens JMP’s event website


The H.C. Wainwright 2nd Annual BioConnect Investor Conference

Location: NASDAQ, Room 2 – Central

Date: Monday, May 20, 2024

Time: 12:30 – 1:00 p.m. ET

Live Webcast: Available on H.C. Wainwright’s event website

During the presentations and one-on-one meetings, Ocugen senior executives will showcase the Company’s recent business and gene therapy clinical development progress including the OCU400 Phase 3 liMeliGhT clinical trial currently underway. OCU400, a modifier gene therapy, is the first gene therapy program to enter Phase 3 with a broad retinitis pigmentosa indication.

A replay of the Citizens JMP & H.C. Wainwright webcasts will be available in the Events section of the Company’s website. 

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

 


FAQ

When will Ocugen present at The Citizens JMP Life Sciences Conference?

Dr. Shankar Musunuri will present at The Citizens JMP Life Sciences Conference from May 13 – 14, 2024.

Where will Dr. Huma Qamar participate in a fireside chat?

Dr. Huma Qamar will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024.

What is the focus of Ocugen's recent business and gene therapy clinical development progress?

Ocugen's recent progress includes the OCU400 Phase 3 liMeliGhT clinical trial, the first gene therapy program to enter Phase 3 for retinitis pigmentosa.

Where can a replay of the webcasts be found?

A replay of the Citizens JMP & H.C. Wainwright webcasts will be available in the Events section of Ocugen's website.

Ocugen, Inc.

NASDAQ:OCGN

OCGN Rankings

OCGN Latest News

OCGN Stock Data

392.47M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
United States of America
MALVERN

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.